Connor, Clark & Lunn Investment Management Ltd. Aptinyx Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $22 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 12, 2020
SELL
$3.05 - $4.99 $31,244 - $51,117
-10,244 Closed
0 $0
Q2 2020

Aug 13, 2020
SELL
$1.99 - $4.4 $18,966 - $41,936
-9,531 Reduced 48.2%
10,244 $43,000
Q1 2020

May 13, 2020
BUY
$1.81 - $5.03 $35,792 - $99,468
19,775 New
19,775 $42,000

About Aptinyx Inc.

APTX Quotes by TradingView
  • Ticker APTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,715,696
  • Description
  • Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...
More about APTX
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email